Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2− Advanced Breast Cancer Enrolled in an Expanded Access Program

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.04.005 ◽

2019 ◽

Vol 19 (5) ◽

pp. 317-325.e4 ◽

Author(s):

Adam Brufsky ◽

Debanjali Mitra ◽

Keith L. Davis ◽

Saurabh P. Nagar ◽

Lynn McRoy ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Treatment Patterns ◽

Advanced Breast ◽

Expanded Access ◽

Expanded Access Program ◽

Download Full-text

449 Capecitabine monotherapy is active, well tolerated and provides convenient outpatient therapy for patients with taxane-pretreated advanced breast cancer: findings from an expanded access program

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90481-2 ◽

2003 ◽

Vol 1 (5) ◽

pp. S137 ◽

Author(s):

M. Venturini ◽

R. Bell ◽

R. Paridaens ◽

D. Rossner ◽

M. Vaslamatzis ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Outpatient Therapy ◽

Expanded Access ◽

Expanded Access Program ◽

Download Full-text

Abstract P5-21-24: Retrospective assessment of treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR+/HER2– advanced breast cancer enrolled in an early access program

10.1158/1538-7445.sabcs17-p5-21-24 ◽

2018 ◽

Author(s):

A Brufsky ◽

K Davis ◽

D Mitra ◽

S Nagar ◽

L McRoy ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Treatment Patterns ◽

Advanced Breast ◽

Early Access ◽

Retrospective Assessment ◽

Download Full-text

Abstract P4-13-05: Safety results of the US expanded access program (EAP) of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) for whom letrozole therapy is deemed appropriate

10.1158/1538-7445.sabcs15-p4-13-05 ◽

2016 ◽

Author(s):

V Stearns ◽

JW Smith II ◽

R Patel ◽

D Lu ◽

JJ Perkins ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Expanded Access ◽

Hormone Receptor Positive ◽

Expanded Access Program ◽

Menopausal Women ◽

The Us ◽

Post Menopausal ◽

Download Full-text

Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2018.07.007 ◽

2018 ◽

Vol 18 (6) ◽

pp. e1239-e1245 ◽

Author(s):

Vered Stearns ◽

Adam M. Brufsky ◽

Shailendra Verma ◽

Matthew J. Cotter ◽

Dongrui R. Lu ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Breast ◽

Expanded Access ◽

Hormone Receptor Positive

Download Full-text

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

Hormone Receptor Positive

Download Full-text

Faculty Opinions recommendation of Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738775672.793581181 ◽

2020 ◽

Author(s):

Jason S Carroll

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Dose Escalation ◽

Advanced Breast ◽

Download Full-text

BRCA status, treatment patterns and outcomes in HER2- advanced breast cancer (ABC): A multi-country real-world study

Annals of Oncology ◽

10.1093/annonc/mdz100.012 ◽

2019 ◽

Vol 30 ◽

pp. iii51-iii52

Author(s):

A. Niyazov ◽

R.G.W. Quek ◽

K. Lewis ◽

J. Kemp ◽

A. Rider

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Treatment Patterns ◽

Advanced Breast

Download Full-text

Clinical Trial of Letrozole (femara) versus Aminoglutethimide in Postmenopausal Women with Advanced Breast Cancer

The Chinese-German Journal of Clinical Oncology ◽

10.1007/s10330-005-0387-4 ◽

2005 ◽

Vol 4 (6) ◽

pp. 338-340

Author(s):

Xiaoqing LIU ◽

Santai SONG ◽

Zefei JIANG ◽

Weilian LI ◽

Weixia WANG ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Advanced Breast

Download Full-text

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

Clinical & Translational Oncology ◽

10.1007/s12094-017-1797-9 ◽

2017 ◽

Vol 20 (7) ◽

pp. 862-869 ◽

Author(s):

I. Blancas ◽

M. Fontanillas ◽

V. Conde ◽

J. Lao ◽

E. Martínez ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Routine Clinical Practice ◽

Advanced Breast

Download Full-text

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽

Hormone Receptor Positive

Download Full-text